公开(公告)号：KR1020090038336A

公开(公告)日：2009-04-20

申请号：KR1020070103779

申请日：2007-10-15

Applicant: 가톨릭대학교 산학협력단 ,  포항공과대학교 산학협력단

Inventor： 김호연 ,  조미라 ,  강창민 ,  문영미 ,  성영철 ,  김두진

IPC: A61K38/20

CPC classification number: A61K38/20 ,  A61K38/1722 ,  C07K14/4717 ,  C07K14/54 ,  C12N15/62 ,  C12N15/63 ,  Y10S424/809 ,  Y10S424/81

Abstract: A pharmaceutical composition containing Interleukin-27, Il-27-Fc fusion protein and mutant thereof is provided to efficiently inhibit production of IL-17 and increase production of IFN-gamma by promoting differentiation of Th-1 in order to treat and prevent autoimmune diseases. A pharmaceutical composition for treatment and prevention of autoimmune diseases comprises Interleukin-27, Il-27-Fc fusion protein and mutant thereof. The Interleukin-27 is human-derived proteins. The pharmaceutical composition contains Il-27-Fc fusion protein wherein carboxyl terminal of the Interleukin-27 is coupled with amino terminal of immunoglobulin Fc and peptide. The immunoglobulin Fc is derived from one selected from the group consisting of IgG, IgA, IgM, IgE and IgD. The immunoglobulin Fc has a hinge site which can has one or more cysteins. The autoimmune diseases represent systemic lupus erythematosus, Sjogren syndrome, Hashimoto thyroiditis, rheumatoid arthritis, polymyositis, scleroderma, Addison disease, vitiligo, pernicious anemia, glomerulonephritis or pulmonary fibrosis.

Abstract translation: 提供了含有白细胞介素-27，II-27-Fc融合蛋白及其突变体的药物组合物，以有效抑制IL-17的产生并通过促进Th-1的分化来增加IFN-γ的产生，从而治疗和预防自身免疫疾病 。 用于治疗和预防自身免疫疾病的药物组合物包含白细胞介素-27，II-27-Fc融合蛋白及其突变体。 白细胞介素-27是人源性蛋白质。 药物组合物含有II-27-Fc融合蛋白，其中白细胞介素-27的羧基末端与免疫球蛋白Fc和肽的氨基末端偶联。 免疫球蛋白Fc来自选自IgG，IgA，IgM，IgE和IgD的一种。 免疫球蛋白Fc具有可以具有一个或多个半胱氨酸的铰链位点。 自身免疫性疾病代表系统性红斑狼疮，干燥综合征，桥本甲状腺炎，类风湿性关节炎，多发性肌炎，硬皮病，艾迪生病，白癜风，恶性贫血，肾小球性肾炎或肺纤维化。

公开(公告)号：KR1020030086429A

公开(公告)日：2003-11-10

申请号：KR1020030028080

申请日：2003-05-01

Applicant: 포항공과대학교 산학협력단 ,  주식회사 제넥신

Inventor： 성영철 ,  하상준 ,  김두진 ,  진현탁

IPC: C12N15/79

CPC classification number: C12N15/79 ,  A61K48/00 ,  A61K2039/53 ,  C12N15/70

Abstract: PURPOSE: Optimal eukaryotic expression vectors are provided, which have optimal conditions for gene therapy and DNA vaccine. Therefore, the vectors containing desired genes are used for gene therapy and DNA vaccine. CONSTITUTION: A foreign gene expression vector comprising ITR, pCMV, TPL, SV40 poly(A), SV40 enhancer, ITR and kan sequentially is provided, wherein the expression vector is pGX30 having the nucleotide sequence of SEQ ID NO: 9. A recombinant vector contains human interleukin-12 mutant(hIL-12m) gene operably linked to downstream of TPL in the vector pGX30, wherein the recombinant vector is pGX30-hIL-12m. Transformed E. coli DH5alpha/pGX30-hp35/IRES/hp40-N222L (KCTC 10232BP) is produced by transforming E. coli with the vector pGX30-hIL-12m. A foreign gene expression vector comprising ITR, pCMV, TPL, bGH poly(A), ITR and Amp sequentially is provided, wherein the expression vector is pACP20 having the nucleotide sequence of SEQ ID NO: 11. A recombinant vector contains hIL-12m gene operably linked to downstream of TPL in the vector pACP20, wherein the recombinant vector is pACP20-hIL-12m. Transformed E. coli DH5alpha/pACP20-hp35/IRES/hp40-N222L (KCTC 10233BP) is produced by transforming E. coli with the vector pACP20-hIL-12m.

Abstract translation: 目的：提供最佳的真核表达载体，其具有基因治疗和DNA疫苗的最佳条件。 因此，含有所需基因的载体用于基因治疗和DNA疫苗。 构成：提供了包含ITR，pCMV，TPL，SV40聚（A），SV40增强子，ITR和kan的外源基因表达载体，其中表达载体是具有SEQ ID NO：9的核苷酸序列的pGX30。重组载体 含有在载体pGX30中可操作地连接于TPL下游的人白细胞介素-12突变体（hIL-12m）基因，其中重组载体是pGX30-hIL-12m。 通过用载体pGX30-hIL-12m转化大肠杆菌来生产转化的大肠杆菌DH5α/ pGX30-hp35 / IRES / hp40-N222L（KCTC 10232BP）。 提供了包含ITR，pCMV，TPL，bGH poly（A），ITR和Amp的外源基因表达载体，其中表达载体是具有SEQ ID NO：11的核苷酸序列的pACP20。重组载体含有hIL-12m基因 在载体pACP20中可操作地连接到TPL的下游，其中重组载体是pACP20-hIL-12m。 通过用载体pACP20-hIL-12m转化大肠杆菌来生产转化的大肠杆菌DH5α/ pACP20-hp35 / IRES / hp40-N222L（KCTC 10233BP）。